Verisk Analytics
VRSK
$169.41
-3.43%
Verisk Analytics is a leading data, analytics, and technology provider exclusively focused on the global property and casualty (P&C) insurance industry, offering critical solutions for underwriting, claims, and catastrophe modeling. The company is a dominant, entrenched player in its niche, functioning as an essential data utility for insurers, which provides it with a highly defensible market position and recurring revenue streams. The current investor narrative is dominated by a significant stock price decline, which appears to be driven by concerns over growth deceleration and margin pressures, as evidenced by recent quarterly results showing a sequential drop in profitability, prompting a reassessment of its premium valuation.…
VRSK
Verisk Analytics
$169.41
Investment Opinion: Should I buy VRSK Today?
Rating: Hold. The core thesis is that VRSK is a high-quality business experiencing a painful but potentially transient fundamental reset; the stock is no longer egregiously overvalued, but the lack of visibility on a margin recovery warrants caution before establishing new positions.
Supporting evidence for this Hold rating includes the compressed forward PE of 21.54x, which is far more reasonable than the trailing 34.24x and reflects lowered expectations. Analyst sentiment, while mixed, retains a bullish lean from key firms. The company's robust TTM free cash flow of $1.19 billion and strong return on assets of 16.46% underscore the underlying quality of the franchise. However, these positives are counterbalanced by the severe Q4 margin collapse and the high absolute PS ratio of 10.12x.
The thesis would upgrade to a Buy if Q1 2026 results show a clear rebound in gross margin back above 65% and revenue growth stabilizes or re-accelerates. It would downgrade to a Sell if margins remain below 60% for a second consecutive quarter or if revenue growth decelerates further below 5% YoY. Based on the current data, the stock appears fairly valued relative to its near-term risk/reward profile—it is no longer overvalued, but not yet demonstrably undervalued given the fundamental uncertainties.
Sign up to view all
VRSK 12-Month Price Forecast
The outlook for VRSK is one of high uncertainty centered on profitability. The stock's violent repricing has created a more balanced risk/reward setup, but the path forward is entirely dependent on the next one or two quarterly reports. The base case is a period of sideways consolidation as the company works to stabilize its operations. The stance is neutral due to the lack of visibility; confidence would increase to high on a bullish stance only after concrete evidence of margin recovery. The investment decision hinges less on valuation and more on the binary outcome of the margin story.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Verisk Analytics's 12-month outlook, with a consensus price target around $220.23 and implied upside of +30.0% versus the current price.
Average Target
$220.23
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$136 - $220
Analyst target range
Analyst coverage for Verisk is limited, with only 7 analysts providing estimates, which is relatively sparse for a company of its market cap and suggests it may be under-followed. The consensus sentiment, based on recent institutional ratings, leans bullish with firms like Raymond James (Strong Buy), RBC Capital (Outperform), JP Morgan (Overweight), and Wells Fargo (Overweight) maintaining positive ratings, though others like Goldman Sachs (Neutral), Morgan Stanley (Equal Weight), and Evercore ISI (In Line) express a more cautious stance. The target price range implied by EPS estimates is narrow, with a high of $9.83 and a low of $9.26, indicating strong consensus on near-term earnings potential, but the lack of a published average price target in the data limits the ability to calculate a precise implied upside or downside from the current stock price.
Bulls vs Bears: VRSK Investment Factors
The investment debate for VRSK centers on a clash between its high-quality, defensive business model and alarming recent fundamental deterioration. The bear case currently holds stronger evidence, as the severe Q4 margin contraction and growth deceleration are concrete, recent data points that directly challenge the core investment thesis of a premium-priced essential utility. The single most important tension is whether the Q4 margin collapse is a one-time anomaly or the beginning of a sustained erosion in profitability. If margins recover, the stock's deep discount presents a compelling opportunity. If not, the high valuation multiples leave ample room for further downside.
Bullish
- Essential Utility with Recurring Revenue: Verisk operates as a critical data and analytics utility for the P&C insurance industry, with 83% of revenue from the US. This entrenched position provides a highly defensible market position and sticky, recurring revenue streams, which is a key pillar of its investment thesis.
- Strong Free Cash Flow Generation: The company generates robust free cash flow, with TTM FCF of $1.19 billion. This provides ample capacity to fund its dividend (payout ratio of 27.6%) and share repurchases, supporting shareholder returns even during a period of stock price weakness.
- Valuation Compression to Forward PE of 21.5x: The stock's trailing PE of 34.24x has compressed significantly from recent highs near 50x. More importantly, the forward PE of 21.54x implies the market expects a meaningful earnings recovery, offering a more reasonable entry point for a historically premium-valued stock.
- Analyst Consensus Remains Bullish: Despite the stock's decline, major institutions like Raymond James (Strong Buy), RBC Capital (Outperform), and JP Morgan (Overweight) maintain positive ratings. This suggests professional analysts see the sell-off as overdone relative to the company's long-term fundamentals.
Bearish
- Severe Gross Margin Contraction in Q4: Q4 2025 gross margin collapsed to 59.6%, down from 70.1% in Q3. This 1,050 basis point sequential decline is a major red flag, indicating potential cost inflation, pricing pressure, or a negative mix shift that directly threatens profitability.
- Revenue Growth Deceleration: Q4 revenue growth slowed to 5.87% YoY, down from 8.7% in Q3. This sequential deceleration, coupled with the margin pressure, validates market concerns about a deteriorating fundamental story and challenges the premium growth narrative.
- Highly Leveraged Balance Sheet: The company carries a debt-to-equity ratio of 16.30, indicating significant financial leverage. While covered by strong FCF, this high leverage amplifies risk if earnings decline, increases interest expense, and limits financial flexibility for strategic moves.
- Sustained Technical Downtrend: The stock is in a severe downtrend, down 38.25% over the past year with a maximum drawdown of -47.26%. It has underperformed the S&P 500 by over 60 percentage points in the last year, reflecting persistent selling pressure and broken investor confidence.
VRSK Technical Analysis
The stock is in a pronounced and sustained downtrend, with a 1-year price change of -38.25%, significantly underperforming the S&P 500's +22.2% gain. As of the latest close of $185.08, the stock is trading near the lower end of its 52-week range, at approximately 11% above its 52-week low of $164.6 and 43% below its 52-week high of $322.92, indicating it is in deep value territory but also reflecting severe negative momentum and potential fundamental concerns. Recent short-term momentum shows continued weakness, with the stock down 13.82% over the past month and 16.26% over the past three months, confirming the longer-term downtrend is still intact and accelerating relative to the market, as evidenced by a -9.54% 1-month relative strength figure. Key technical support is clearly defined at the 52-week low of $164.6, while major resistance sits at the 52-week high of $322.92; a sustained breakdown below the $164.6 support level would signal a new phase of decline, whereas any recovery would first need to contend with the significant overhead supply created during the steep fall. With a beta of 0.819, the stock has been less volatile than the market during this downturn, but its -47.26% maximum drawdown highlights the extreme absolute price damage that has occurred.
Beta
0.82
0.82x market volatility
Max Drawdown
-47.3%
Largest decline past year
52-Week Range
$165-$323
Price range past year
Annual Return
-41.4%
Cumulative gain past year
| Period | VRSK Return | S&P 500 |
|---|---|---|
| 1m | -16.4% | +0.4% |
| 3m | -24.7% | -2.0% |
| 6m | -30.3% | +4.1% |
| 1y | -41.4% | +23.9% |
| ytd | -23.4% | -0.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
VRSK Fundamental Analysis
Revenue growth remains positive but has shown signs of sequential deceleration and margin pressure; Q4 2025 revenue of $778.8 million grew 5.87% year-over-year, but this represents a slowdown from the 8.7% growth in the prior quarter (Q3 2025), and gross margin contracted sharply to 59.6% in Q4 from 70.1% in Q3. Profitability metrics have weakened considerably in the most recent quarter, with net income of $197.2 million and a net margin of 25.3% in Q4, down significantly from Q3's net income of $225.5 million and a 29.4% net margin, indicating compression in both gross and operating profitability. The balance sheet is leveraged, with a high debt-to-equity ratio of 16.30, but the company generates robust free cash flow, with TTM free cash flow of $1.19 billion providing ample coverage for its dividend and share repurchases, as evidenced by a current ratio of 1.20 and a strong return on assets of 16.46% signaling efficient use of its capital base.
Quarterly Revenue
$778800000.0B
2025-12
Revenue YoY Growth
+0.05%
YoY Comparison
Gross Margin
+0.59%
Latest Quarter
Free Cash Flow
$1.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is VRSK Overvalued?
Given the company's consistent profitability, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE ratio stands at 34.24x, while the forward PE is notably lower at 21.54x, indicating the market expects a significant rebound in earnings over the next twelve months. Compared to its own historical range, the current trailing PE of 34.24x is below the multi-year highs seen in recent quarters (e.g., 49.69x at the end of 2023) but remains elevated relative to the lows near 17x in early 2022, suggesting the valuation has compressed but may not yet be at a historical bargain level if earnings estimates are revised down. The stock trades at a Price-to-Sales ratio of 10.12x and an EV/EBITDA of 20.12x; without a direct industry average provided, the high absolute multiples, particularly on a trailing basis, suggest the market has historically awarded Verisk a premium for its niche dominance and recurring revenue model, which is now being tested.
PE
34.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 17x~130x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
20.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are pronounced and center on profitability. The shocking Q4 gross margin contraction from 70.1% to 59.6% represents a direct threat to the company's premium valuation, which is predicated on high, stable margins. Furthermore, the high debt-to-equity ratio of 16.30, while manageable with current cash flow, creates vulnerability to rising interest rates and could constrain strategic investments if free cash flow weakens. Revenue concentration in the US P&C insurance market (83%) also presents a cyclical and regulatory risk, though this is inherent to its niche dominance.
Market & Competitive Risks are elevated due to valuation. Despite the 38% price decline, VRSK still trades at a trailing PE of 34.24x and a PS ratio of 10.12x. These are premium multiples that require a resumption of strong growth and margin expansion to be sustained. The stock's beta of 0.819 suggests it is less volatile than the market, but its -47.26% max drawdown shows it has been highly volatile to its own specific fundamentals. The primary risk is multiple compression if the market re-rates the stock from a high-growth analytics play to a slower-growth utility, a process that appears to have begun but may not be complete.
Worst-Case Scenario involves a continuation of the Q4 trends, leading to a full derating. In this scenario, revenue growth stalls below 5%, margins fail to recover, and forward earnings estimates are cut. This could trigger a wave of analyst downgrades from the currently bullish cohort. The stock could re-test and break its 52-week low of $164.60, representing a further -11% decline from the current $185.08. A more severe bear case, applying a market-average PE to depressed earnings, could see the stock fall towards the $150-$160 range, implying a total realistic downside risk of -13% to -19% from current levels.
FAQ
The key risks are, in order of severity: 1) Profitability Risk: The Q4 gross margin crash from 70.1% to 59.6% could be structural, leading to permanently lower earnings power. 2) Valuation Risk: High multiples (PS 10.12x, EV/EBITDA 20.12x) are vulnerable to compression if growth slows. 3) Financial Risk: The high debt-to-equity ratio of 16.30 increases vulnerability to rising rates and earnings volatility. 4) Business Concentration Risk: 83% of revenue is tied to the US P&C insurance industry, making it susceptible to sector-specific downturns or regulatory changes.
The 12-month forecast is bifurcated, with outcomes heavily dependent on margin recovery. The base case (55% probability) sees the stock trading between $200 and $230 as growth stabilizes at ~5-6% and margins partially recover. The bull case (25% probability) could drive the stock to $260-$290 on a full margin rebound and re-rating. The bear case (20% probability) risks a fall to $165-$185 if profitability continues to deteriorate. The most likely scenario is the base case, which assumes the company manages to stop the bleeding but does not quickly return to its former high-margin glory, leading to a period of consolidation.
VRSK is in a transition from overvalued to fairly valued. Its trailing PE of 34.24x and PS ratio of 10.12x remain elevated in an absolute sense, suggesting the market still ascribes some premium for its niche. However, the forward PE of 21.54x indicates significant earnings growth is expected and that much of the valuation excess has been wrung out. Compared to its own history, it is cheaper than its 2023 highs but not yet at bargain-basement levels seen in early 2022. The current valuation fairly reflects a company with strong cash flow but serious near-term profitability questions. It is no longer clearly overvalued, but not demonstrably undervalued either.
VRSK is a speculative buy at current levels, suitable only for investors with a high risk tolerance and a long-term horizon. The 38% decline has improved the valuation (forward PE of 21.5x), and the company's underlying utility-like business model is strong. However, it is not a 'good buy' for everyone due to the severe and unresolved margin collapse evidenced in Q4. The potential upside to analyst-informed base targets (~$215) offers about 16% upside, but the downside to the 52-week low ($164.6) is -11%. It could be a good buy for contrarians who believe the margin issue is temporary, but most investors should wait for proof of stabilization in the next quarterly report.
VRSK is strictly a long-term investment at this juncture, with a suggested minimum holding period of 2-3 years. The company is in the midst of a fundamental reassessment, and the next few quarters are likely to be volatile as the margin story unfolds. Its low beta of 0.819 is misleading given the stock-specific 47% drawdown. The modest dividend yield of 0.8% does not provide meaningful income support for short-term holders. Only investors willing to look through near-term turbulence to the potential long-term recovery of a dominant franchise should consider a position. It is unsuitable for short-term trading due to the high uncertainty and event-driven volatility around earnings.